uniQure announced on Tuesday that the FDA has accepted three-year Phase I/II data from AMT-130 as the primary basis for a Biologics License Application under accelerated approval. The BLA submission is targeted for Q3 2026. That sentence represents a complete reversal from where things stood in March, when the FDA told uniQure its Phase I/II data compared against an external control were not sufficient to support a marketing application. The agency’s more recent Type B meeting produced a materially different position: the 3-year analysis can serve as the primary evidence of effectiveness, provided uniQure aligns with FDA on the confirmatory study design before submission. YourNewsClub notes the Type A to Type B trajectory as the compressed regulatory pivot that made Tuesday’s announcement possible – a meeting series that moved from “insufficient” to “submit this quarter” in less than four months.
AMT-130 is a one-time gene therapy delivered by surgical injection directly into the striatum, the region of the brain most affected by Huntington’s disease. It uses an adeno-associated virus vector to deliver a microRNA that reduces production of huntingtin protein, the accumulation of which drives neurodegeneration. In the Phase I/II trial, AMT-130 produced a statistically significant 75% slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale at 36 months, against a propensity score-matched external control. uniQure also announced a parallel Pre-Submission Meeting with the UK’s MHRA and plans to file a Marketing Authorization Application in the same Q3 2026 window. The stock rose sharply on the news.
The context of failure is worth naming directly. In January 2026, uniQure held a Type A meeting with FDA specifically to discuss the BLA package. The FDA’s response, delivered in March, was a formal statement that it could not agree the Phase I/II data were sufficient – and a strong recommendation that uniQure conduct a prospective, randomised, double-blind, sham surgery-controlled study. That is a multi-year undertaking in a disease where patients have little time. CEO Matt Kapusta committed to engaging with FDA after that setback, and the company’s continued clinical engagement produced a different signal: in a subsequent Type B meeting, FDA communicated that the 3-year analysis would in fact be acceptable as the primary basis. YourNewsClub scores that shift as the single most consequential regulatory about-face in neurology in 2026 – a company that received a hard no in March is now targeting an FDA submission in September.
Owen Radner, who models digital infrastructure as energy-information transport systems, draws the systems distinction: “Gene therapy approval pathways are infrastructure problems as much as clinical ones. AMT-130 delivers a payload once, irreversibly. The regulatory framework for irreversible single-dose neurological interventions does not have established precedent the way chronic-medication frameworks do. FDA’s shift from requiring a sham-controlled study to accepting Phase I/II data for accelerated approval is itself a policy development, not just a product decision.” Jessica Larn, who studies macro-level technology policy and infrastructure impact, draws the reimbursement architecture forward: “An accelerated approval for AMT-130 is not the end of the approval story – it triggers a requirement for a confirmatory study. The commercial window depends entirely on whether payer systems in the US and UK will cover a gene therapy priced for Huntington’s before that confirmatory study completes. That is the next phase of this regulatory-commercial negotiation.”
The uncomfortable version of this story is this: accelerated approval for AMT-130, if granted, will place a therapy on the market before the confirmatory study completes. Patients may receive it, payers may cover it, and physicians may administer it before the controlled evidence that FDA originally said it needed actually exists. YourNewsClub clocks the confirmatory study design alignment – which FDA has committed to work on “expeditiously” ahead of the Q3 submission – as the next formal milestone, and expects the FDA’s proposed study parameters to reveal how much clinical burden the agency will impose before full approval.
The neurodegenerative disease desk at Your News Club will map the BLA submission date and FDA review timeline as the two variables that determine whether AMT-130 reaches US patients before the end of 2027.